Anti一 ilnmunosuppressive drugs including cyclosporineA and cyclophosphamide have been used for the management of frequency relapse llephrotic syndrome(FRNS) HO、 vever, there is the limitation of the usage of such agents because of the cytotoxic advers effects Moreover iong-time use of the same immunosuppressive agent may induce the tachyphylaxis The aim of this study is to determine the efficacy and saFety of mizoribille, a relatively lle、 vly developed immunOsuppressive agent in 」apan fOr the

more »

... anagement of FRNS Single divided of 5 mg/kg of mizOribin(max 150 mg/day)was given to the patients at morning and serum concentration of this drug、 vas measured 2 hours after administration 22 patiellts with FRNS (relapse i 9 and remisslon 13)、 vere enrolled in this study Their mean age(years)/mean bOdy weight(kg)/mean mizoHbine dose(mg/kg/day)/mean mizOribine serum concentration (μ g/ml)was 17 1/49 5/3 23/1 56 and 9 8/27 9/4 63/2 93, respectively This study may suggested that mizoribine is effective for the suppression Of the relapse in patients、 vith FRNS, especially in children beloH′ than 10 years and 30kg of body weight Key words i mizoribille, frequency relapse nephrotic sylldrome(FRNS), Oral pulse therapy, C2 3(3)